Cyclophosphamide and etoposide for advanced head and neck cancer after first chemotherapy
Tests cyclophosphamide with etoposide in adults whose advanced head and neck cancer worsened.
Plain-language title generated from the registry record
Registry title: Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 2
Where in Egypt
- National Cancer InstituteCairo, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Cancer Institute, Egypt
- Trial code
- NCT07361133
- Record updated
- 16 April 2026
- Original description
The goal of this clinical trial is to learn if drugs as cyclophosphamide (C) and etoposide (E) work to treat advanced head and neck cancer in adults. It will also learn about the safety of both drugs. The main questions it aims to answer are:Read full original descriptionShow less
Cyclophosphamide and Etoposide as a Promising Metronomic Therapy in Advanced Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to learn if drugs as cyclophosphamide (C) and etoposide (E) work to treat advanced head and neck cancer in adults. It will also learn about the safety of both drugs. The main questions it aims to answer are:
Do drugs C and E work to treat advanced head and neck cancer, after failure on first line chemotherapy? What medical problems do participants have when taking drugs C and E? Researchers will compare drugs C and E in combination to a placebo (a look-alike substance that contains no drug) to see if these 2 drugs works to treat advanced head and neck cancer.
Participants will:
Take drug C every 3 weeks and drug E every 4 weeks or a placebo every week for 6 months.
Visit the clinic once every 3 weeks for checkups and tests. Keep a diary of their symptoms.
Inclusion: Adult participants, age = or > 18 years; Participants with recurrent head and neck squamous cell carcinoma after failure on first line chemotherapy; Participants with advanced progressed, resistant, metastatic head and neck squamous cell carcinoma.
Exclusion: Adjuvant and Neoadjuvant head and neck squamous cell carcinoma patients.